Peptide intra-tumor injection for cancer immunotherapy

Enhancement of tumor cell antigenicity is a novel and attractive strategy

Daisuke Nobuoka, Toshiaki Yoshikawa, Toshiyoshi Fujiwara, Tetsuya Nakatsura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

One of the problems in antigen-specific cancer immunotherapy is the low density of the tumor antigen-derived peptide endogenously presented on tumor cell surface major histocompatibility complex class I molecules. To overcome this, we are engaged in research on peptide intra-tumor injection to enhance tumor cell antigenicity. In in vivo studies using immunodeficient mice, the peptide injected into a solid mass of subcutaneous tumor was revealed to be loaded onto human leukocyte antigen class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, peptide intra-tumor injection was effective in terms of tumor growth inhibition and prolongation of survival time. Moreover, an antigen-spreading effect was detected after peptide intra-tumor injection. Peptide intra-tumor injection is an effective method of enhancing tumor cell antigenicity. It can induce additional peptide loading onto tumor cells, making tumor cells more antigenic for specific cytotoxic T-lymphocyte activity. Peptide intra-tumor injection may be a useful option for improvement of antigen-specific immunotherapy against solid tumors.

Original languageEnglish
Pages (from-to)1234-1236
Number of pages3
JournalHuman Vaccines and Immunotherapeutics
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Immunotherapy
Peptides
Injections
Neoplasms
Antigens
Subunit Vaccines
Adoptive Transfer
Cytotoxic T-Lymphocytes
Neoplasm Antigens
HLA Antigens
Major Histocompatibility Complex
Inbred C57BL Mouse

Keywords

  • Antigen-derived peptide
  • Cancer immunotherapy
  • Cytotoxic T lymphocyte
  • Major histocompatibility complex class I
  • Tumor antigen

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Peptide intra-tumor injection for cancer immunotherapy : Enhancement of tumor cell antigenicity is a novel and attractive strategy. / Nobuoka, Daisuke; Yoshikawa, Toshiaki; Fujiwara, Toshiyoshi; Nakatsura, Tetsuya.

In: Human Vaccines and Immunotherapeutics, Vol. 9, No. 6, 06.2013, p. 1234-1236.

Research output: Contribution to journalArticle

@article{2947fccb77204029a456db73f95e12ea,
title = "Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy",
abstract = "One of the problems in antigen-specific cancer immunotherapy is the low density of the tumor antigen-derived peptide endogenously presented on tumor cell surface major histocompatibility complex class I molecules. To overcome this, we are engaged in research on peptide intra-tumor injection to enhance tumor cell antigenicity. In in vivo studies using immunodeficient mice, the peptide injected into a solid mass of subcutaneous tumor was revealed to be loaded onto human leukocyte antigen class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, peptide intra-tumor injection was effective in terms of tumor growth inhibition and prolongation of survival time. Moreover, an antigen-spreading effect was detected after peptide intra-tumor injection. Peptide intra-tumor injection is an effective method of enhancing tumor cell antigenicity. It can induce additional peptide loading onto tumor cells, making tumor cells more antigenic for specific cytotoxic T-lymphocyte activity. Peptide intra-tumor injection may be a useful option for improvement of antigen-specific immunotherapy against solid tumors.",
keywords = "Antigen-derived peptide, Cancer immunotherapy, Cytotoxic T lymphocyte, Major histocompatibility complex class I, Tumor antigen",
author = "Daisuke Nobuoka and Toshiaki Yoshikawa and Toshiyoshi Fujiwara and Tetsuya Nakatsura",
year = "2013",
month = "6",
doi = "10.4161/hv.23990",
language = "English",
volume = "9",
pages = "1234--1236",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Peptide intra-tumor injection for cancer immunotherapy

T2 - Enhancement of tumor cell antigenicity is a novel and attractive strategy

AU - Nobuoka, Daisuke

AU - Yoshikawa, Toshiaki

AU - Fujiwara, Toshiyoshi

AU - Nakatsura, Tetsuya

PY - 2013/6

Y1 - 2013/6

N2 - One of the problems in antigen-specific cancer immunotherapy is the low density of the tumor antigen-derived peptide endogenously presented on tumor cell surface major histocompatibility complex class I molecules. To overcome this, we are engaged in research on peptide intra-tumor injection to enhance tumor cell antigenicity. In in vivo studies using immunodeficient mice, the peptide injected into a solid mass of subcutaneous tumor was revealed to be loaded onto human leukocyte antigen class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, peptide intra-tumor injection was effective in terms of tumor growth inhibition and prolongation of survival time. Moreover, an antigen-spreading effect was detected after peptide intra-tumor injection. Peptide intra-tumor injection is an effective method of enhancing tumor cell antigenicity. It can induce additional peptide loading onto tumor cells, making tumor cells more antigenic for specific cytotoxic T-lymphocyte activity. Peptide intra-tumor injection may be a useful option for improvement of antigen-specific immunotherapy against solid tumors.

AB - One of the problems in antigen-specific cancer immunotherapy is the low density of the tumor antigen-derived peptide endogenously presented on tumor cell surface major histocompatibility complex class I molecules. To overcome this, we are engaged in research on peptide intra-tumor injection to enhance tumor cell antigenicity. In in vivo studies using immunodeficient mice, the peptide injected into a solid mass of subcutaneous tumor was revealed to be loaded onto human leukocyte antigen class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, peptide intra-tumor injection was effective in terms of tumor growth inhibition and prolongation of survival time. Moreover, an antigen-spreading effect was detected after peptide intra-tumor injection. Peptide intra-tumor injection is an effective method of enhancing tumor cell antigenicity. It can induce additional peptide loading onto tumor cells, making tumor cells more antigenic for specific cytotoxic T-lymphocyte activity. Peptide intra-tumor injection may be a useful option for improvement of antigen-specific immunotherapy against solid tumors.

KW - Antigen-derived peptide

KW - Cancer immunotherapy

KW - Cytotoxic T lymphocyte

KW - Major histocompatibility complex class I

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=84880682913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880682913&partnerID=8YFLogxK

U2 - 10.4161/hv.23990

DO - 10.4161/hv.23990

M3 - Article

VL - 9

SP - 1234

EP - 1236

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 6

ER -